Caris Life Sciences, Inc.
CAI
$27.24
$1.134.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.53% | 50.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.53% | 50.02% | |||
| Cost of Revenue | 2.38% | 6.05% | |||
| Gross Profit | 29.75% | 99.23% | |||
| SG&A Expenses | -12.55% | 15.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.62% | 11.47% | |||
| Operating Income | 281.46% | 68.96% | |||
| Income Before Tax | 133.88% | 30.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 133.88% | 30.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 133.88% | 30.02% | |||
| EBIT | 281.46% | 68.96% | |||
| EBITDA | 423.94% | 77.25% | |||
| EPS Basic | 101.08% | -123.39% | |||
| Normalized Basic EPS | 110.40% | 71.19% | |||
| EPS Diluted | 101.00% | -123.39% | |||
| Normalized Diluted EPS | 109.87% | 71.19% | |||
| Average Basic Shares Outstanding | 334.54% | 82.24% | |||
| Average Diluted Shares Outstanding | 357.82% | 82.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||